Research map: Metabolic dysfunction profiles identify heterogeneous hepatocellular carcinoma risk in MASLD-associated advanced fibrosis

Back to the article

Papers in this map

  1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature · Mary Eugenia Rinella · 2023 · 3032 citations · Cited by this paper
  2. Reply to: Correspondence on “Longitudinal changes in cardiometabolic risk factors are associated with changes in liver stiffness in adults with MASLD” · Matthew Dukewich · 2026 · Cites this paper
  3. Quantitative Bias Analysis of Unmeasured Confounding Refines Interpretation of Longitudinal Associations Between Cardiometabolic Risk Factors and Liver Stiffness in MASLD · 2026 · Related
  4. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma · Bruno Sangro · 2024 · 887 citations · Cited by this paper
  5. Updates in clinical science: Alcohol-related hepatitis · 2026 · Related
  6. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis · Amit G. Singal · 2022 · 450 citations · Cited by this paper
  7. Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction · 2026 · Related
  8. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States · Donghee Kim · 2021 · 424 citations · Cited by this paper
  9. OSM-STAT3 signaling facilitates Long-term expansion of Pediatric Hepatic Organoids · 2026 · Related
  10. Heterogeneity of liver cancer and personalized therapy · Liang Li · 2015 · 354 citations · Cited by this paper
  11. JHEP at a glance (August 2026) · 2026 · Related
  12. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease · Fasiha Kanwal · 2019 · 323 citations · Cited by this paper
  13. Before repurposing Fusobacterium nucleatum in alcohol-associated liver disease: it is a rare, non-resident organism in the human alcoholic gut · 2026 · Related
  14. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies · Tracey G. Simon · 2017 · 163 citations · Cited by this paper
  15. Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort · 2026 · Related
  16. Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes? · Mengqi Li · 2023 · 44 citations · Cited by this paper
  17. Non-selective β-blockers reduce bacterial translocation by restoring gut barrier function during experimental cirrhosis · 2026 · Related
  18. Longitudinal changes in cardiometabolic risk factors are associated with changes in liver stiffness in adults with MASLD · Matthew Dukewich · 2026 · 11 citations · Cited by this paper
  19. Revisiting rejection after immune checkpoint inhibitor exposure prior to liver transplantation for hepatocellular carcinoma · 2026 · Related
  20. Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis · 2026 · Related

Source: OpenAlex (CC0)